Andrew Schiermeier, AvenCell Therapeutics CEO
October 22, 2024 06:00 AM EDTUpdated 06:29 AM
Financing
Cell/Gene Tx

Aven­Cell gets $112M to build switch­able CAR-T ther­a­pies for ‘the last fron­tier’ of blood can­cers

Lei Lei Wu

News Reporter

Aven­Cell Ther­a­peu­tics on Tues­day said it col­lect­ed $112 mil­lion to con­tin­ue clin­i­cal stud­ies of two ex­per­i­men­tal acute myeloid leukemia CAR-T cell ther­a­pies.

The Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times